Risk factor
Very poor trading liquidity
Profitability factor
Favourable analyst view
About
Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITD
Target Price
The average target price of ATRY.MC is 5.8 and suggests 109% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell